Open Access
Review
Lifting the Veil on Myeloma Bone Disease
Rui Chen1
, Rui Liu1
, Huan Liu1, 2, *
Author Information
Submitted: 13 Nov 2024 | Revised: 29 Nov 2024 | Accepted: 13 Jan 2025 | Published: 23 Jan 2025
Abstract
Multiple myeloma (MM), a hematological malignancy originating from malignant plasma cells in the bone marrow, predominantly affects the elderly, and its incidence is on the rise. It is currently the second most common hematological malignancy. Osteolytic bone disease, a severe complication detected in nearly 80% of myeloma patients, affects the entire skeletal system, particularly the skull, spine, pelvis, and long bones of the limbs. This condition causes pathological fractures, severe bone pain, spinal cord compression, and hypercalcemia. The management of bone damage in myeloma patients presents numerous challenges, with current clinical treatments primarily relying on bisphosphonates and anti-RANKL monoclonal antibodies (Denosumab). This review summarizes recent advancements in research on myeloma and bone damage, focusing on the complex interactions between myeloma cells and various other cell types that affect the skeleton. It also discusses the challenges encountered in bone damage research, highlighting potential future research directions and proposing therapeutic strategies.
Graphical Abstract
Keywords
References
1.
Palumbo, A.; Anderson, K. Multiple myeloma. N. Engl. J. Med. 2011, 364, 1046–1060. https://doi.org/10.1056/NEJMra1011442.
2.
Tian, E.; Zhan, F.; Walker, R.; Rasmussen, E.; Ma, Y.; Barlogie, B.; Shaughnessy, J.D., Jr. The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma. N. Engl. J. Med. 2003, 349, 2483–2494. https://doi.org/10.1056/NEJMoa030847.
3.
Liu, H.; Liu, Z.; Du, J.; He, J.; Lin, P.; Amini, B.; Starbuck, M.W.; Novane, N.; Shah, J.J.; Davis, R.E.; et al. Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma. Sci. Transl. Med. 2016, 8, 353ra113. https://doi.org/10.1126/scitranslmed.aad8949.
4.
Giuliani, N.; Rizzoli, V.; Roodman, G.D. Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood 2006, 108, 3992–3996. https://doi.org/10.1182/blood-2006-05-026112.
5.
Roodman, G.D. Biology of osteoclast activation in cancer. J. Clin. Oncol. 2001, 19, 3562–3571. https://doi.org/10.1200/JCO.2001.19.15.3562.
6.
Terpos, E.; Berenson, J.; Raje, N.; Roodman, G.D. Management of bone disease in multiple myeloma. Expert. Rev. Hematol. 2014, 7, 113–125. https://doi.org/10.1586/17474086.2013.874943.
7.
Abe, M.; Hiura, K.; Wilde, J.; Shioyasono, A.; Moriyama, K.; Hashimoto, T.; Kido, S.; Oshima, T.; Shibata, H.; Ozaki, S.; et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: A vicious cycle between bone destruction and myeloma expansion. Blood 2004, 104, 2484–2491. https://doi.org/10.1182/blood-2003-11-3839.
8.
Barille, S.; Collette, M.; Bataille, R.; Amiot, M. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood 1995, 86, 3151–3159. https://doi.org/10.1182/blood.V86.8.3151.3151.
9.
Giuliani, N.; Colla, S.; Morandi, F.; Lazzaretti, M.; Sala, R.; Bonomini, S.; Grano, M.; Colucci, S.; Svaldi, M.; Rizzoli, V. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005, 106, 2472–2483. https://doi.org/10.1182/blood-2004-12-4986.
10.
Liu, H.; Wang, Z.; He, J.; Li, Z.; Gao, J.Y.; Liu, R.; Lin, P.; Yang, J. Promotion of Bone Lesions Through the Myeloma Integrin α6-Mediated Osteolytic Signaling. Front. Oncol. 2021, 11, 692190. https://doi.org/10.3389/fonc.2021.692190.
11.
Liu, Z.; Liu, H.; He, J.; Lin, P.; Tong, Q.; Yang, J. Myeloma cells shift osteoblastogenesis to adipogenesis by inhibiting the ubiquitin ligase MURF1 in mesenchymal stem cells. Sci. Signal. 2020, 13, eaay8203. https://doi.org/10.1126/scisignal.aay8203.
12.
Michigami, T.; Shimizu, N.; Williams, P.J.; Niewolna, M.; Dallas, S.L.; Mundy, G.R.; Yoneda, T. Cell–cell contact between marrow stromal cells and myeloma cells via VCAM-1 and α4β1-integrin enhances production of osteoclast-stimulating activity. Blood 2000, 96, 1953–1960. https://doi.org/10.1182/blood.V96.5.1953.
13.
Mori, Y.; Shimizu, N.; Dallas, M.; Niewolna, M.; Story, B.; Williams, P.J.; Mundy, G.R.; Yoneda, T. Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 2004, 104, 2149–2154. https://doi.org/10.1182/blood-2004-01-0236.
14.
Diamond, P.; Labrinidis, A.; Martin, S.K.; Farrugia, A.N.; Gronthos, S.; To, L.B.; Fujii, N.; O'Loughlin, P.D.; Evdokiou, A.; Zannettino, A.C.W. Targeted Disruption of the CXCL12/CXCR4 Axis Inhibits Osteolysis in a Murine Model of Myeloma-Associated Bone Loss. J. Bone Miner. Res. 2009, 24, 1150–1161. https://doi.org/10.1359/jbmr.090210.
15.
Faict, S.; Muller, J.; De Veirman, K.; De Bruyne, E.; Maes, K.; Vrancken, L.; Heusschen, R.; De Raeve, H.; Schots, R.; Vanderkerken, K.; et al. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. Blood Cancer J. 2018, 8, 105. https://doi.org/10.1038/s41408-018-0139-7.
16.
Giannoni, P.; de Totero, D. The HGF/c-MET axis as a potential target to overcome survival signals and improve therapeutic efficacy in multiple myeloma. Cancer Drug Resist. 2021, 4, 923–933. https://doi.org/10.20517/cdr.2021.73.
17.
Giuliani, N.; Lisignoli, G.; Colla, S.; Lazzaretti, M.; Storti, P.; Mancini, C.; Bonomini, S.; Manferdini, C.; Codeluppi, K.; Facchini, A.; et al. CC-Chemokine Ligand 20/Macrophage Inflammatory Protein-3α and CC-Chemokine Receptor 6 Are Overexpressed in Myeloma Microenvironment Related to Osteolytic Bone Lesions. Cancer Res. 2008, 68, 6840–6850. https://doi.org/10.1158/0008-5472.Can-08-0402.
18.
He, J.; Liu, Z.; Zheng, Y.; Qian, J.; Li, H.; Lu, Y.; Xu, J.; Hong, B.; Zhang, M.; Lin, P.; et al. p38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction. Cancer Res. 2012, 72, 6393–6402. https://doi.org/10.1158/0008-5472.Can-12-2664.
19.
Kaiser, M.; Mieth, M.; Liebisch, P.; Oberländer, R.; Rademacher, J.; Jakob, C.; Kleeberg, L.; Fleissner, C.; Braendle, E.; Peters, M.; et al. Serum concentrations of DKK‐1 correlate with the extent of bone disease in patients with multiple myeloma. Eur. J. Haematol. 2008, 80, 490–494. https://doi.org/10.1111/j.1600-0609.2008.01065.x.
20.
Lee, J.W.; Chung, H.Y.; Ehrlich, L.A.; Jelinek, D.F.; Callander, N.S.; Roodman, G.D.; Choi, S.J. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2004, 103, 2308–2315. https://doi.org/10.1182/blood-2003-06-1992.
21.
Liu, R.; Zhong, Y.; Chen, R.; Chu, C.; Liu, G.; Zhou, Y.; Huang, Y.; Fang, Z.; Liu, H. m6A reader hnRNPA2B1 drives multiple myeloma osteolytic bone disease. Theranostics 2022, 12, 7760–7774. https://doi.org/10.7150/thno.76852.
22.
Qiang, Y.-W.; Chen, Y.; Stephens, O.; Brown, N.; Chen, B.; Epstein, J.; Barlogie, B.; Shaughnessy, J.D. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: A potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008, 112, 196–207. https://doi.org/10.1182/blood-2008-01-132134.
23.
Raimondi, L.; De Luca, A.; Fontana, S.; Amodio, N.; Costa, V.; Carina, V.; Bellavia, D.; Raimondo, S.; Siragusa, S.; Monteleone, F.; et al. Multiple Myeloma-Derived Extracellular Vesicles Induce Osteoclastogenesis through the Activation of the XBP1/IRE1α Axis. Cancers 2020, 12, 2167. https://doi.org/10.3390/cancers12082167.
24.
Raimondo, S.; Saieva, L.; Vicario, E.; Pucci, M.; Toscani, D.; Manno, M.; Raccosta, S.; Giuliani, N.; Alessandro, R. Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis. J. Hematol. Oncol. 2019, 12, 2. https://doi.org/10.1186/s13045-018-0689-y.
25.
Raje, N.S.; Bhatta, S.; Terpos, E. Role of the RANK/RANKL Pathway in Multiple Myeloma. Clin. Cancer Res. 2019, 25, 12–20. https://doi.org/10.1158/1078-0432.Ccr-18-1537.
26.
Seckinger, A.; Meiβner, T.; Moreaux, J.; Depeweg, D.; Hillengass, J.; Hose, K.; Rème, T.; Rösen-Wolff, A.; Jauch, A.; Schnettler, R.; et al. Clinical and prognostic role of annexin A2 in multiple myeloma. Blood 2012, 120, 1087–1094. https://doi.org/10.1182/blood-2012-03-415588.
27.
Sun, C.Y.; Chu, Z.B.; She, X.M.; Zhang, L.; Chen, L.; Ai, L.S.; Hu, Y. Brain‐derived neurotrophic factor is a potential osteoclast stimulating factor in multiple myeloma. Int. J. Cancer 2011, 130, 827–836. https://doi.org/10.1002/ijc.26059.
28.
Tang, W.; Xu, J.; Xu, C. Noncoding RNAs in the crosstalk between multiple myeloma cells and bone marrow microenvironment. Cancer Lett. 2023, 556, 216081. https://doi.org/10.1016/j.canlet.2023.216081.
29.
Vallet, S.; Pozzi, S.; Patel, K.; Vaghela, N.; Fulciniti, M.T.; Veiby, P.; Hideshima, T.; Santo, L.; Cirstea, D.; Scadden, D.T.; et al. A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia 2011, 25, 1174–1181. https://doi.org/10.1038/leu.2011.43.
30.
Zhang, L.; Lei, Q.; Wang, H.; Xu, C.; Liu, T.; Kong, F.; Yang, C.; Yan, G.; Sun, L.; Zhao, A.; et al. Tumor-derived extracellular vesicles inhibit osteogenesis and exacerbate myeloma bone disease. Theranostics 2019, 9, 196–209. https://doi.org/10.7150/thno.27550.
31.
Delgado-Calle, J.; Anderson, J.; Cregor, M.D.; Hiasa, M.; Chirgwin, J.M.; Carlesso, N.; Yoneda, T.; Mohammad, K.S.; Plotkin, L.I.; Roodman, G.D.; et al. Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma. Cancer Res. 2016, 76, 1089–1100. https://doi.org/10.1158/0008-5472.Can-15-1703.
32.
Fowler, J.A.; Edwards, C.M.; Croucher, P.I. Tumor–host cell interactions in the bone disease of myeloma. Bone 2011, 48, 121–128. https://doi.org/10.1016/j.bone.2010.06.029.
33.
Giuliani, N.; Colla, S.; Sala, R.; Moroni, M.; Lazzaretti, M.; La Monica, S.; Bonomini, S.; Hojden, M.; Sammarelli, G.; Barillè, S.; et al. Human myeloma cells stimulate the receptor activator of nuclear factor-κB ligand (RANKL) in T lymphocytes: A potential role in multiple myeloma bone disease. Blood 2002, 100, 4615–4621. https://doi.org/10.1182/blood-2002-04-1121.
34.
Liu, H.; He, J.; Bagheri-Yarmand, R.; Li, Z.; Liu, R.; Wang, Z.; Bach, D.; Huang, Y.; Lin, P.; Guise, T.A.; et al. Osteocyte CIITA aggravates osteolytic bone lesions in myeloma. Nat. Commun. 2022, 13, 3684. https://doi.org/10.1038/s41467-022-31356-7.
35.
Liu, H.; He, J.; Koh, S.P.; Zhong, Y.; Liu, Z.; Wang, Z.; Zhang, Y.; Li, Z.; Tam, B.T.; Lin, P.; et al. Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease. Sci. Transl. Med. 2019, 11, eaau9087. https://doi.org/10.1126/scitranslmed.aau9087.
36.
Noonan, K.; Marchionni, L.; Anderson, J.; Pardoll, D.; Roodman, G.D.; Borrello, I. A novel role of IL-17–producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 2010, 116, 3554–3563. https://doi.org/10.1182/blood-2010-05-283895.
37.
Vallet, S.; Mukherjee, S.; Vaghela, N.; Hideshima, T.; Fulciniti, M.; Pozzi, S.; Santo, L.; Cirstea, D.; Patel, K.; Sohani, A.R.; et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc. Natl. Acad. Sci. USA 2010, 107, 5124–5129. https://doi.org/10.1073/pnas.0911929107.
38.
Yang, J.; Liu, Z.; Liu, H.; He, J.; Yang, J.; Lin, P.; Wang, Q.; Du, J.; Ma, W.; Yin, Z.; et al. C-reactive protein promotes bone destruction in human myeloma through the CD32–p38 MAPK–Twist axis. Sci. Signal. 2017, 10, eaan6282. https://doi.org/10.1126/scisignal.aan6282.
39.
Teramachi, J.; Miki, H.; Nakamura, S.; Hiasa, M.; Harada, T.; Abe, M. Myeloma bone disease: Pathogenesis and management in the era of new anti-myeloma agents. J. Bone Miner. Metab. 2023, 41, 388–403. https://doi.org/10.1007/s00774-023-01403-4.
40.
Terpos, E.; Roodman, G.D.; Dimopoulos, M.A. Optimal use of bisphosphonates in patients with multiple myeloma. Blood 2013, 121, 3325–3328. https://doi.org/10.1182/blood-2012-10-435750.
41.
Terpos, E.; Confavreux, C.B.; Clezardin, P. Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma. Bonekey Rep. 2015, 4, 744. https://doi.org/10.1038/bonekey.2015.113.
42.
Yaccoby, S. Osteoblastogenesis and tumor growth in myeloma. Leuk. Lymphoma 2009, 51, 213–220. https://doi.org/10.3109/10428190903503438.
43.
Daponte, V.; Henke, K.; Drissi, H. Current perspectives on the multiple roles of osteoclasts: Mechanisms of osteoclast–osteoblast communication and potential clinical implications. eLife 2024, 13, e95083. https://doi.org/10.7554/eLife.95083.
44.
Mao, L.; Wang, L.; Xu, J.; Zou, J. The role of integrin family in bone metabolism and tumor bone metastasis. Cell Death Discov. 2023, 9, 119. https://doi.org/10.1038/s41420-023-01417-x.
45.
Jones, P.A. Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 2012, 13, 484–492. https://doi.org/10.1038/nrg3230.
46.
Garcia-Gomez, A.; Li, T.; de la Calle-Fabregat, C.; Rodriguez-Ubreva, J.; Ciudad, L.; Catala-Moll, F.; Godoy-Tena, G.; Martin-Sanchez, M.; San-Segundo, L.; Muntion, S.; et al. Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease. Nat. Commun. 2021, 12, 421. https://doi.org/10.1038/s41467-020-20715-x.
47.
Raimondo, S.; Urzi, O.; Conigliaro, A.; Bosco, G.L.; Parisi, S.; Carlisi, M.; Siragusa, S.; Raimondi, L.; Luca, A.; Giavaresi, G.; et al. Extracellular Vesicle microRNAs Contribute to the Osteogenic Inhibition of Mesenchymal Stem Cells in Multiple Myeloma. Cancers 2020, 12, 449. https://doi.org/10.3390/cancers12020449.
48.
Guo, N.; Song, Y.; Zi, F.; Zheng, J.; Cheng, J. Abnormal expression pattern of lncRNA H19 participates in multiple myeloma bone disease by unbalancing osteogenesis and osteolysis. Int. Immunopharmacol. 2023, 119, 110058. https://doi.org/10.1016/j.intimp.2023.110058.
49.
Salhotra, A.; Shah, H.N.; Levi, B.; Longaker, M.T. Mechanisms of bone development and repair. Nat. Rev. Mol. Cell Biol. 2020, 21, 696–711. https://doi.org/10.1038/s41580-020-00279-w.
50.
Long, F. Building strong bones: Molecular regulation of the osteoblast lineage. Nat. Rev. Mol. Cell Biol. 2011, 13, 27–38. https://doi.org/10.1038/nrm3254.
51.
Terpos, E.; Ntanasis-Stathopoulos, I.; Gavriatopoulou, M.; Dimopoulos, M.A. Pathogenesis of bone disease in multiple myeloma: From bench to bedside. Blood Cancer J. 2018, 8, 7. https://doi.org/10.1038/s41408-017-0037-4.
52.
Takegahara, N.; Kim, H.; Choi, Y. Unraveling the intricacies of osteoclast differentiation and maturation: Insight into novel therapeutic strategies for bone-destructive diseases. Exp. Mol. Med. 2024, 56, 264–272. https://doi.org/10.1038/s12276-024-01157-7.
53.
Zheng, H.; Liu, Y.; Deng, Y.; Li, Y.; Liu, S.; Yang, Y.; Qiu, Y.; Li, B.; Sheng, W.; Liu, J.; et al. Recent advances of NFATc1 in rheumatoid arthritis-related bone destruction: Mechanisms and potential therapeutic targets. Mol. Med. 2024, 30, 20. https://doi.org/10.1186/s10020-024-00788-w.
54.
Fu, J.; Li, S.; Ma, H.; Yang, J.; Pagnotti, G.M.; Brown, L.M.; Weiss, S.J.; Mapara, M.Y.; Lentzsch, S. The checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease. Nat. Commun. 2023, 14, 4271. https://doi.org/10.1038/s41467-023-39769-8.
55.
Zahoor, M.; Westhrin, M.; Aass, K.R.; Moen, S.H.; Misund, K.; Psonka-Antonczyk, K.M.; Giliberto, M.; Buene, G.; Sundan, A.; Waage, A.; et al. Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss. Blood Adv. 2017, 1, 2656–2666. https://doi.org/10.1182/bloodadvances.2017010801.
56.
Spanoudakis, E.; Papoutselis, M.; Terpos, E.; Dimopoulos, M.A.; Tsatalas, C.; Margaritis, D.; Rahemtulla, A.; Kotsianidis, I.; Karadimitris, A. Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma. Blood Cancer J. 2016, 6, e500. https://doi.org/10.1038/bcj.2016.108.
57.
Fu, J.; Li, S.; Feng, R.; Ma, H.; Sabeh, F.; Roodman, G.D.; Wang, J.; Robinson, S.; Guo, X.E.; Lund, T.; et al. Multiple myeloma–derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease. J. Clin. Investig. 2016, 126, 1759–1772. https://doi.org/10.1172/jci80276.
58.
Westhrin, M.; Kovcic, V.; Zhang, Z.; Moen, S.H.; Nedal, T.M.V.; Bondt, A.; Holst, S.; Misund, K.; Buene, G.; Sundan, A.; et al. Monoclonal immunoglobulins promote bone loss in multiple myeloma. Blood 2020, 136, 2656–2666. https://doi.org/10.1182/blood.2020006045.
59.
Wang, H.; Wang, L.; Luan, H.; Xiao, J.; Zhao, Z.; Yu, P.; Deng, M.; Liu, Y.; Ji, S.; Ma, J.; et al. LILRB4 on multiple myeloma cells promotes bone lesion by p-SHP2/NF-kappaB/RELT signal pathway. J. Exp. Clin. Cancer Res. 2024, 43, 183. https://doi.org/10.1186/s13046-024-03110-y.
60.
Yu, M.; Cai, Z.; Zhang, J.; Zhang, Y.; Fu, J.; Cui, X. Aberrant NSUN2-mediated m5C modification of exosomal LncRNA MALAT1 induced RANKL-mediated bone destruction in multiple myeloma. Commun. Biol. 2024, 7, 1249. https://doi.org/10.1038/s42003-024-06918-8.
61.
Dallas, S.L.; Prideaux, M.; Bonewald, L.F. The osteocyte: An endocrine cell ... and more. Endocr. Rev. 2013, 34, 658–690. https://doi.org/10.1210/er.2012-1026.
62.
van Bezooijen, R.L.; Roelen, B.A.; Visser, A.; van der Wee-Pals, L.; de Wilt, E.; Karperien, M.; Hamersma, H.; Papapoulos, S.E.; ten Dijke, P.; Lowik, C.W. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 2004, 199, 805–814. https://doi.org/10.1084/jem.20031454.
63.
Anloague, A.; Sabol, H.M.; Kaur, J.; Khan, S.; Ashby, C.; Schinke, C.; Barnes, C.L.; Alturkmani, F.; Ambrogini, E.; Gundesen, M.T.; et al. Novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma. Haematologica 2024. https://doi.org/10.3324/haematol.2024.286484.
64.
Liu, R.; Zhong, Y.; Chen, R.; Chen, S.; Huang, Y.; Liu, H. Bacterial infections exacerbate myeloma bone disease. J. Transl. Med. 2022, 20, 16. https://doi.org/10.1186/s12967-021-03187-5.
65.
Hillengass, J.; Usmani, S.; Rajkumar, S.V.; Durie, B.G.M.; Mateos, M.-V.; Lonial, S.; Joao, C.; Anderson, K.C.; García-Sanz, R.; Riva, E.; et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019, 20, e302–e312,. https://doi.org/10.1016/s1470-2045(19)30309-2.
66.
Baysoy, A.; Bai, Z.; Satija, R.; Fan, R. The technological landscape and applications of single-cell multi-omics. Nat. Rev. Mol. Cell Biol. 2023, 24, 695–713. https://doi.org/10.1038/s41580-023-00615-w.
67.
de Jong, M.M.E.; Kellermayer, Z.; Papazian, N.; Tahri, S.; Hofste Op Bruinink, D.; Hoogenboezem, R.; Sanders, M.A.; van de Woestijne, P.C.; Bos, P.K.; Khandanpour, C.; et al. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. Nat. Immunol. 2021, 22, 769–780. https://doi.org/10.1038/s41590-021-00931-3.
68.
Hussain, M.; Khan, F.; Al Hadidi, S. The use of bone-modifying agents in multiple myeloma. Blood Rev. 2023, 57, 100999. https://doi.org/10.1016/j.blre.2022.100999.
69.
Rogers, M.J.; Monkkonen, J.; Munoz, M.A. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Bone 2020, 139, 115493. https://doi.org/10.1016/j.bone.2020.115493.
70.
Terpos, E.; Zamagni, E.; Lentzsch, S.; Drake, M.T.; Garcia-Sanz, R.; Abildgaard, N.; Ntanasis-Stathopoulos, I.; Schjesvold, F.; de la Rubia, J.; Kyriakou, C.; et al. Treatment of multiple myeloma-related bone disease: Recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol. 2021, 22, e119–e130. https://doi.org/10.1016/S1470-2045(20)30559-3.
71.
Choksi, P.; Williams, M.; Clark, P.M.; Van Poznak, C. Skeletal Manifestations of Treatment of Breast Cancer. Curr. Osteoporos. Rep. 2013, 11, 319–328. https://doi.org/10.1007/s11914-013-0179-7.
72.
Ogawa, T.; Ohshika, S.; Yanagisawa, M.; Kurose, A.; Ishibashi, Y. Teriparatide may accelerate the growth of a pre-existing malignant tumor in an elderly patient with osteoporosis: A case report. Mol. Clin. Oncol. 2020, 12, 144–147. https://doi.org/10.3892/mco.2019.1966.
73.
Ong, K.L.; Villarraga, M.L.; Lau, E.; Carreon, L.Y.; Kurtz, S.M.; Glassman, S.D. Off-Label Use of Bone Morphogenetic Proteins in the United States Using Administrative Data. Spine 2010, 35, 1794–1800. https://doi.org/10.1097/BRS.0b013e3181ecf6e4.
74.
Skovrlj, B.; Koehler, S.M.; Anderson, P.A.; Qureshi, S.A.; Hecht, A.C.; Iatridis, J.C.; Cho, S.K. Association Between BMP-2 and Carcinogenicity. Spine 2015, 40, 1862–1871. https://doi.org/10.1097/BRS.0000000000001126.
75.
Hiraga, T.; Horibe, K.; Koide, M.; Yamashita, T.; Kobayashi, Y. Sclerostin blockade promotes bone metastases of Wnt-responsive breast cancer cells. Cancer Sci. 2023, 114, 2460–2470. https://doi.org/10.1111/cas.15765.
76.
McClung, M.R.; Brown, J.P.; Diez-Perez, A.; Resch, H.; Caminis, J.; Meisner, P.; Bolognese, M.A.; Goemaere, S.; Bone, H.G.; Zanchetta, J.R.; et al. Effects of 24 Months of Treatment with Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study. J. Bone Miner. Res. 2018, 33, 1397–1406. https://doi.org/10.1002/jbmr.3452.
77.
Zavrski, I.; Krebbel, H.; Wildemann, B.; Heider, U.; Kaiser, M.; Possinger, K.; Sezer, O. Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem. Biophys. Res. Commun. 2005, 333, 200–205. https://doi.org/10.1016/j.bbrc.2005.05.098.
78.
Terpos, E.; Kastritis, E.; Ntanasis-Stathopoulos, I.; Christoulas, D.; Papatheodorou, A.; Eleutherakis-Papaiakovou, E.; Kanellias, N.; Fotiou, D.; Ziogas, D.C.; Migkou, M.; et al. Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. Am. J. Hematol. 2019, 94, 400–407. https://doi.org/10.1002/ajh.25392.
79.
Hurchla, M.A.; Garcia-Gomez, A.; Hornick, M.C.; Ocio, E.M.; Li, A.; Blanco, J.F.; Collins, L.; Kirk, C.J.; Piwnica-Worms, D.; Vij, R.; et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia 2013, 27, 430–440. https://doi.org/10.1038/leu.2012.183.
80.
Terpos, E.; Ntanasis-Stathopoulos, I.; Katodritou, E.; Kyrtsonis, M.C.; Douka, V.; Spanoudakis, E.; Papatheodorou, A.; Eleutherakis-Papaiakovou, E.; Kanellias, N.; Gavriatopoulou, M.; et al. Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study. Cancers 2021, 13, 1257. https://doi.org/10.3390/cancers13061257.
81.
Wang, Q.; Dong, Z.; Su, J.; Huang, J.; Xiao, P.; Tian, L.; Chen, Y.; Ma, L.; Chen, X. Ixazomib inhibits myeloma cell proliferation by targeting UBE2K. Biochem. Biophys. Res. Commun. 2021, 549, 1–7. https://doi.org/10.1016/j.bbrc.2021.02.048.
82.
Tibullo, D.; Longo, A.; Vicario, N.; Romano, A.; Barbato, A.; Di Rosa, M.; Barbagallo, I.; Anfuso, C.D.; Lupo, G.; Gulino, R.; et al. Ixazomib Improves Bone Remodeling and Counteracts sonic Hedgehog signaling Inhibition Mediated by Myeloma Cells. Cancers 2020, 12, 323. https://doi.org/10.3390/cancers12020323.
83.
Diaz-delCastillo, M.; Gundesen, M.T.; Andersen, C.W.; Nielsen, A.L.; Moller, H.E.H.; Vinholt, P.J.; Asmussen, J.T.; Kristensen, I.B.; Nyvold, C.G.; Abildgaard, N.; et al. Increased Bone Volume by Ixazomib in Multiple Myeloma: 3-Month Results from an Open Label Phase 2 Study. J. Bone Miner. Res. 2023, 38, 639–649. https://doi.org/10.1002/jbmr.4807.
84.
Dhillon, S. Narlumosbart: First Approval. Drugs 2024, 84, 105–109. https://doi.org/10.1007/s40265-023-01985-3.
85.
Liao, J.; Han, R.; Wu, Y.; Qian, Z. Review of a new bone tumor therapy strategy based on bifunctional biomaterials. Bone Res. 2021, 9, 18. https://doi.org/10.1038/s41413-021-00139-z.
86.
Iaquinta, M.R.; Mazzoni, E.; Bononi, I.; Rotondo, J.C.; Mazziotta, C.; Montesi, M.; Sprio, S.; Tampieri, A.; Tognon, M.; Martini, F. Adult Stem Cells for Bone Regeneration and Repair. Front. Cell Dev. Biol. 2019, 7, 268. https://doi.org/10.3389/fcell.2019.00268.
87.
Duan, X.-P.; Qin, B.-D.; Jiao, X.-D.; Liu, K.; Wang, Z.; Zang, Y.-S. New clinical trial design in precision medicine: Discovery, development and direction. Signal Transduct. Target. Ther. 2024, 9, 57. https://doi.org/10.1038/s41392-024-01760-0.
Issue
Volume 2, Issue 1How to Cite
Chen, R., Liu, R., & Liu, H. (2025). Lifting the Veil on Myeloma Bone Disease. Health and Metabolism, 2(1), 5. https://doi.org/10.53941/hm.2025.100005
RIS
BibTex
Copyright & License
Copyright (c) 2025 by the authors.
This work is licensed under a This work is licensed under a Creative Commons Attribution 4.0 International License.